The Women’s Health Market Outlook to 2016

Date: May 22, 2011
Pages: 111
Price:
US$ 3,835.00
Publisher: Business Insights
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: WBEF01ECB46EN
Leaflet:

Download PDF Leaflet

The Women’s Health Market Outlook to 2016
Price
Global License: US$ 14,780.00


Introduction

The Women’s Health Market Outlook to 2016 provides comprehensive coverage of the women’s health market, a incorporating disease overview and detailed epidemiological analyses of the major indications. This report makes an in-depth assessment of marketed products, R&D pipelines, market share data, sales forecast and the competitive landscape for the major players.

Features and benefits
  • Understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive market changes.
  • Compare the franchises of the leading companies in global women's health market, and understand how the market share of these companies will change.
  • Assess key pipeline products by indication, ongoing trials, recent product launches and key developments in R&D.
  • Identify the challenges confronted by leading players, and learn from their business strategies.
  • Forecast of the leading marketed and pipeline products through to 2015.
Highlights

The global women’s health market in 2010 was valued at $23.3bn, with a CAGR of 4.2% (2005–10). It is forecasted to reach $32.8bn by 2016 at a CAGR of 5.9% (2010–16).

Hormonal contraceptives was the largest selling drug class in 2010 and is projected to reach $15.2bn by 2016. This class is dominated by generics and branded generic products. Osteoporosis treatment is the second largest drug class and consists of many blockbuster brands like Fosamax, Actonel, Evista, Bonvivia.

The top 10 brands in the women’s health market accounted for 39.5% of total sales in 2010. Seven out of the top 10 brands are forecasted to decline during the forecast period due to impending or expired patents.

Your key questions answered
  • What will be the major growth indications and the accompanying growth drivers in the women’s health market to 2016?
  • Which were the leading players in the women’s health market in 2010? Which companies are best positioned to succeed to 2016?
  • Which therapeutic categories and products are forecast to have the highest levels of commercial potential over the period 2010-16?
  • What is a successful commercial and marketing strategy in the women's health market?
  • What are the significant market and pipeline developments that may shape corporate strategies for leading drug majors in this market?
Executive Summary
  Overview and epidemiology of women’s health
  Global market analysis
  Pipeline analysis
  Competitive landscape
About the author
  Disclaimer
Overview and epidemiology of women’s health
  Summary
  Introduction
  Osteoporosis
    Overview
    Diagnosis treatment and management
    Epidemiology
    Forecast epidemiology
  Hormonal contraception
    Overview
    Diagnosis treatment and management
    Epidemiology
    Forecast epidemiology
  Hormone replacement therapies
    Overview
    Diagnosis, treatment and management
  Infertility treatment
    Overview
    Diagnosis, treatment and management
    Epidemiology
    Forecast epidemiology
Global market analysis
  Summary
  Market analysis by geography
  Market analysis by therapy area
    Hormonal contraceptives
    Osteoporosis treatment
    Hormone replacement therapy (HRT)
    Infertility treatment
  Key events in women’s health market
    Merck Serono sells women's health division to Teva
    Gedeon Richter extends women's health franchise with PregLem acquisition
    Boehringer Ingelheim discontinued the development of its female desire drug, flibanserin
    Eli Lilly's arzoxifene misses secondary endpoint in critical osteoporosis trial
    Bayer’s Yaz and Yasmin get US label update
    Research deal between Bayer and Chinese hospital for women's health
  Leading brand dynamics
    Actonel (Risedronate) – Warner Chilcott, Sanofi
    Evista (raloxifene) – Eli Lilly
    Bonviva/Boniva (ibandronic acid) – Roche/GlaxoSmithKline
    Premarin (conjugated estrogens) – Pfizer
    Fosamax (alendronate) – Merck & Co
    Yaz/Yasmin (drospirenone + ethinyl estradiol) – Bayer
    Mirena (levonorgestrel) – Bayer
    Gonal F (follitropin beta) – Merck KGaA
    NuvaRing (ethinyl estradiol + etonogestrel) – Merck & Co.
  Global women’s health sales forecast
Pipeline analysis
  Summary
  Introduction
  Women’s health pipeline
  Leading drugs in development
  Profiles of key pipeline products
    Prolia (denosumab) – Amgen
    Viviant/Conbriza (bazedoxifene) – Pfizer
    LCS (ultra low-dose levonorgestrel releasing IUD) – Bayer
    Aprela (bazedoxifene and conjugated estrogen) – Pfizer
    MK-0822 (odanacatib) – Merck
    Elonva (corifollitropin alfa) – Merck
    Nomac E2 (nomegestrol and estradiol) – Merck & Co.
    WC3026/ Generess (norethindrone + ethinyl estradiol) – Warner Chilcott/Watson
    Natazia/Qlaira (estradiol valerate and dienogest) – Bayer
    SMC021 (synthetic oral salmon calcitonin) – Novartis
    FC Patch Low (gestodene and ethinyl estradiol transdermal patch) – Bayer
    DR2011 (progesterone vaginal ring) – Teva
    EllaOne (ulipristal acetate) – HRA Pharma/Watson
  Pipeline forecast of leading drugs in development
Competitive landscape
  Summary
  Introduction
  Sales performance of leading players
  Bayer
    Marketed product portfolio
    Pipeline analysis
    Strategic and growth analysis
  Merck & Co.
    Marketed product portfolio
    Pipeline analysis
    Strategic and growth analysis
  Eli Lilly
    Marketed product portfolio
    Pipeline analysis
    Strategic and growth analysis
  Warner Chilcott
    Marketed product portfolio
    Pipeline analysis
    Strategic and growth analysis
  Pfizer
    Marketed product portfolio
    Pipeline analysis
    Strategic and growth analysis
  Teva
    Marketed product portfolio
    Pipeline analysis
    Strategic and growth analysis
Appendix
  Scope
    Key women’s health diseases covered in this report
  Methodology
  Epidemiology forecast
  Market forecast
  Epidemiology forecast
  References
    Journal articles
    Conference proceedings
    Important websites
  Glossary/abbreviations
Skip to top


U.S. Market for Women's Health Devices 2011 US$ 7,495.00 Jul, 2011 · 413 pages
Japanese Market for Women's Health Devices 2009 US$ 7,495.00 Oct, 2009 · 250 pages

Ask Your Question

The Women’s Health Market Outlook to 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: